GlassScriptPhysician profile
Caleb B Bozeman
NPI 1881669513
$135,675.99
in general payments reported to CMS, 2019-2025
42 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $28K · 2021: $24K · 2022: $26K · 2023: $1,678 · 2024: $16K · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,224 · Travel and Lodging: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $5,223.99 |
| Travel and Lodging | $584.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cryo Specialty Medical, LLC | $124,500.00 | 2019-2024 | |
| Coloplast Corp | $3,377.80 | 2019-2025 | Titan |
| Boston Scientific Corporation | $1,071.78 | 2020-2024 | Ams 700 Cxr Rte Kit, Ams 700 |
| Sumitomo Pharma America, INC. | $726.57 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $708.95 | 2019-2023 | Myrbetriq, Xtandi |
| Teleflex LLC | $515.96 | 2021-2025 | Urolift, Barrigel |
| Axonics, INC. | $511.42 | 2020-2023 | Axonics, Bulkamid |
| Pfizer INC. | $472.33 | 2019-2025 | |
| Abbvie INC. | $389.26 | 2019-2024 | Botox, Lupron Depot |
| Myovant Sciences INC. | $329.14 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $328.53 | 2019-2024 | Provenge |
| Myriad Genetic Laboratories, INC. | $323.75 | 2022-2025 | Myrisk, Prolaris |
| Blue Earth Diagnostics | $271.19 | 2019-2024 | |
| Tolmar, INC. | $238.67 | 2023-2024 | |
| Janssen Biotech, INC. | $193.64 | 2022-2025 | Erleada, Akeega |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $188.04 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $174.31 | 2019-2024 | Xiaflex, Aveed |
| Medtronic USA, INC. | $155.74 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.64 | 2019-2025 | |
| Allergan, INC. | $132.71 | 2019-2021 | |
| Antares Pharma, INC. | $130.78 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Urogen Pharma, INC. | $84.86 | 2021-2025 | Jelmyto |
| Amgen INC. | $75.64 | 2019-2021 | |
| Caris Mpi, INC. | $67.16 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $63.65 | 2021-2024 | Lynparza, Keytruda |
| Procept Biorobotics Corporation | $58.86 | 2024 | Aquabeam System |
| Ferring Pharmaceuticals INC. | $49.83 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $38.74 | 2023-2025 | Trelstar |
| Astrazeneca Pharmaceuticals LP | $38.48 | 2022-2024 | Lynparza |
| C. R. Bard, INC. & Subsidiaries | $37.16 | 2019 | |
| Endo USA, INC. | $36.24 | 2024-2025 | Xiaflex |
| Medtronic, INC. | $36.13 | 2021-2025 | Interstim |
| Novartis Pharmaceuticals Corporation | $33.66 | 2025 | |
| Urovant Sciences INC | $30.80 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $23.71 | 2022 | |
| Angiodynamics, INC. | $22.10 | 2024 | Nanoknife |
| Travere Therapeutics, INC. | $19.39 | 2021 | |
| Immunitybio, INC. | $18.99 | 2025 | |
| Novo Nordisk INC | $16.99 | 2024 | Rivfloza |
| Cure Medical LLC | $16.55 | 2020 | |
| Halozyme INC | $15.93 | 2023 | |
| Civco Medical Instruments | $13.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$394,464.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Bozeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.